Lupus anticoagulants and the risk of a first episode of deep venous thrombosis

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 9, 2005, Pages 1993-1997

  De Groot, Philip G ^a   Lutters, B ^a   Derksen, R H W M ^a   Lisman, T ^a   Meijers, J C M ^b   Rosendaal, F R ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti 2 glycoprotein I antibodies; Antiprothrombin antibodies; Lupus anticoagulant; Venous thrombosis

Indexed keywords

GLYCOPROTEIN IIB; LUPUS ANTICOAGULANT; PROTHROMBIN ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CLOTTING TEST; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; CASE-CONTROL STUDIES; FEMALE; GLYCOPROTEINS; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; ODDS RATIO; PROTHROMBIN; RISK FACTORS; VENOUS THROMBOSIS;

EID: 30644461619     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01485.x     Document Type: Article

References (20)

1. Nordstrøm M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60.
2. Bertina RM. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem 1997; 43: 1678-83.
3. Roubey RA. Update on antiphospholipid antibodies. Curr Opin Rheumatol 2000; 12: 74-8.
4. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-32.
5. Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003; 1: 931-42.
6. 2- Glycoproteine I. Thromb Haemost 1992; 67; 499-502.
7. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1992; 66: 629-32.
8. Galli M, Luciani D, Bertolini G, Barbui T. Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-23.
9. Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-91.
10. Simioni P, Prandoni P, Zanon E, Saracino MA, Scudeller A, Villalta S, Scarano L, Girolami B, Benedetti L, Girolami A. Deep venous thrombosis and lupus anticoagulant. A case-control study. Thromb Haemost 1996; 76: 187-9.
11. Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992; 23: 189-93.
12. van der Meer FJ, Koster T, Vandenbroucke JP, Briët E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78: 631-35.
13. Horbach DA, van Oort E, Donders RC, Derksen RHWM, de Groot PhG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. J Thromb Haemost 1996; 76: 916-24.
14. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
15. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-3.
16. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19: 251-3.
17. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-98.
18. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus 1997; 6: 467-73.
19. Runchey SS, Folsom AR, Tsai MY, Cushman M, McGovern PD. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 2002; 119: 1005-10.
20. Male C, Mitchell L, Julian J, Vegh P, Joshua P, Adams M, David M, Andrew ME. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001; 97: 844-9.